CatenaBio Presents Poster on Multi-Payload Conjugates at the American Association for Cancer Research (AACR) Annual Meeting

April 8, 2024 | San Diego, CA

ADCs have had tremendous impact on patient outcomes. However, many patients fail to respond or relapse after treatment with ADC therapies. Here we show a novel conjugation system capable of attaching distinct payloads at different sites to the same antibody, enabling the production of stable single molecule targeted combination therapies, Multi-Payload Conjugates, with a well-defined drug-antibody ratio.

View Poster

About Catena Biosciences

CatenaBio began operations in May 2021 and is based on technology developed in the Doudna and Francis Labs at the University of California, Berkeley. The company’s patented CysTyr® platform enables the fusion of novel biomolecules in any structure, combination, or orientation —the only limitation is imagination. With an initial focus in oncology, the platform has applications across multiple therapeutic areas. Catena Bio is the recipient of an NIH SBIR grant and the American Cancer Society’s BrightEdge Golden Ticket at UC Berkeley’s Bakar Labs. Its investors include Amgen, Social Impact Capital, the California Innovation Fund, Gaingels, NYBC Ventures, MBX Capital, Reinforced Ventures, and the American Cancer Society. For more information, please visit catenabio.com or follow us on LinkedIn.

Contact:

Investors

Saurabh Johri
saurabh@catenabio.com

Media

Colin Sanford
colin@bioscribe.com